Anthropic said on 27 October 2026 that its scientists have spent the past several months in deep research partnerships with six organizations developing new medicines, and that it has acquired Mithril Medicine, a one-person company developing treatments for two rare forms of muscular dystrophy, to run drug programs of its own.
The six drug developers are BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group, according to Anthropic’s research post. “We plan to scale this work up substantially from here,” the company wrote.
Short explainer · Anthropic in drug development
A vertical news Short narrated from the published text of this piece and related FourWeekMBA pieces.
Business Pill · AI agents
An evergreen Business Engineer explainer on AI agents: software that moves from answering questions to doing tasks. It explains the general idea and does not discuss Anthropic’s drug-development work.
The key insight: As we read it, Anthropic is moving from selling a model to drug developers to working inside their programs, and with Mithril Medicine to running drug programs of its own.
Anthropic’s post frames drug development as many separate tasks, from choosing a target and designing a molecule to manufacturing, regulatory filings and clinical trials. “There is no single problem to solve; the bottlenecks are distributed all throughout the drug development process,” it says.
Its stated approach is to get “deeply involved in real drug programs, across many different disease areas and stages of development.” Anthropic says the work lets it test its models on a wider range of tasks, gives the industry case studies, and could lead directly to new medicines.
The company says it has already prioritized specific improvements to its models based on what it has learned so far.
Anthropic’s six partner programs and its own, placed by drug-development stage as Anthropic’s 27 October 2026 post describes them. Figures are the companies’ own and come from early, mostly preclinical work; the placement on one line is ours.
What Was Posted on X
Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We’ve also begun drug discovery efforts of our own.
In doing so, weโve learned much more about how Claude can support the many stages of drug development.
In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences.
Anthropic’s official account posted on 27 October 2026 that its scientists have engaged in deep research partnerships with six organizations developing new medicines and that it has begun drug discovery efforts of its own, linking to the research post this piece reports.
Just one day after filing for its IPO, Anthropic announces itโs getting into drug discovery ITSELF.
so basically the AI company that sells tokens to an entire industry may eventually compete with its own customers.
A post on X by @Hesamation (โฮตsam) notes that Anthropic announced its move into drug discovery one day after filing for its IPO, and argues that a company selling tokens to an entire industry may eventually compete with its own customers. That is the poster’s view, not a statement by Anthropic.
Sam Altman’s one-person company prediction is coming true. Anthropic just bought one. The founder of Mithril Medicine used Claude to take a muscular dystrophy antibody treatment from concept to proof-of-principle in mice in 18 months, with just himself, Claude, and part-time consultants. The technical report is great. I will quote:
‘The week opened with the handover of two cell-based assays, cell adhesion and flow cytometry, within our team, while eleven questions remained open with the assay CRO. In two sentences, one of us asked Claude to review the latest emails between the outgoing assay lead and the assay CRO and to recommend next steps for the handover, and gave it the link to the handover folder. Claude returned a bottom line after 96s and a full plan with five drafted emails after 18 min. For the full plan it read six email threads, the handover folder, two slide decks and two reports, all in the mailbox and file store to which we had given it access. Four working days later, nine of the eleven questions had an answer in writing and the other two had been left to pilot experiments. The adhesion screen was thereby set out in writing. The CRO drew the plate map to the format that our team had requested, Claude compiled the run order and the material calculation from the production data, and one of us reviewed and approved them.
On day 4, the production CRO delivered its data package, a report of 341 pages, which one of us forwarded to Claude in two sentences, with the request to review it, share observations and recommend next steps. Claude returned a bottom line after 2 min 40s and, once it had read every page, a visual synthesis of all 113 constructs after 7 min 53s. The synthesis arranged the constructs on the grid of 14 by 8 arms. Claude marked 82 constructs for screening as is, seven for additional polishing, and the 24 constructs of three laminin-binding arms to be held back from the cell-based assays on production criteria. Each of the 113 constructs thus had a proposed next step in less than 8 min.
Claude had recommended binding kinetics for all 113 con-structs, and on day 7 one of us challenged this plan. Claude defended it within 27s, arguing that affinity would show whether the three arms merit further work. One of us overruled this recommendation and set the three arms aside on production criteria. Their material remains in storage. Four minutes later, Claude had revised its memo, the working page, the run order and three unsent drafts from 113 to 89 constructs. It had also applied the ruling to three dependent steps in the unsent drafts, each flagged for our veto. The exchange took 7 min 36s from challenge to new plan, and every affected email was still an unsent draft. After the ruling, eight emails drafted by Claude went out on the same day to three CROs and a consultant.
Over the whole week, Claude drafted 17 emails, each in answer to a request from one of us, and we sent 12 of them, each after editing. With its drafts, Claude listed 41 points, such as tube fills, shipping conditions, recipients and assay settings, for which it had found no written statement of ours, so that we could confirm, change or strike each before sending. We kept some, struck others and changed one. Among the passages that we kept were proposals for controls. One draft proposed a comparison of polished and unpolished material on one sensor chip, to size the error that impurities cause in the rest of the panel. Another requested a buffer control diluted like the most dilute sample, so that any effect of the buffer appears at its largest. These proposals concerned the measurement of constructs that had already been produced, and each reached a CRO only after one of us had reviewed and approved it.
Andrew Curran says Sam Altman’s one-person company prediction is coming true and that Anthropic just bought one. He writes that Mithril Medicine’s founder used Claude to take a muscular dystrophy antibody treatment from concept to proof-of-principle in mice in 18 months, with himself, Claude and part-time consultants.
SITUATION DETECTED: Anthropic acquired a one-person company in July 2026. Mithril Medicine – developing treatments for two rare forms of muscular dystrophy – owned and run by one person who used Claude to organize contracts, logistics, and experiments with 11 external labs.
MTS posted on X that Anthropic acquired Mithril Medicine, a one-person company, in July 2026. Per the post, Mithril is developing treatments for two rare forms of muscular dystrophy, and its one owner used Claude to organize contracts, logistics and experiments with 11 external labs.
Six Partners, Six Stages
Enveda’s manufacturing document review in Anthropic’s test: human review time fell 89%, from over 25 hours to under three, and Claude caught all 11 issues human reviewers had found plus seven they had missed, over 1,061 pages. Source: Anthropic, 27 October 2026.
Anthropic lists one case study per partner, each at a different stage of drug development. The figures below are the ones Anthropic and its partners report; most of the work is preclinical.
The Column Group (company creation). The Column Group is establishing Pleiades, a new company that Anthropic says will use Claude to run many more, and more complex, drug programs than is usual for a small team. Its first Claude skill, which assesses whether drug targets are worth pursuing, has been evaluated on 45 target-disease pairs, the post says.
Generate Biomedicines (modality engineering). Six Generate scientists used Claude Code to propose new designs for one part of a CAR T-cell cancer therapy. Anthropic says one design was about 70% shorter than the standard version and performed better in lab tests.
Divergence Labs (hit generation). For a food-allergy program, Anthropic says Claude turned Divergence’s goals into a designplan and, largely autonomously, generated roughly 35,000 antibody designs in about a month for the company to narrow down and test.
BigHat Biosciences (lead optimization). With Claude connected to BigHat’s lab data system, the company’s lab made and tested about 1,010 variants of two leads in about 10 weeks, according to the post.
Enveda (manufacturing and filings). Anthropic says Enveda’s manufacturing chemists spent up to 75% of their time on paperwork. Over tests on 1,061 pages of documentation, Claude caught all 11 issues that human reviewers had spotted and flagged seven they had missed, cutting human review time by 89%, from over 25 hours to less than three. Claude also wrote first drafts of two regulatory documents; one took four hours, compared with about three months by hand.
Bristol Myers Squibb (clinical trial planning). BMS is using Claude to assess the plans of an early-stage drug in clinical trials and to estimate the likelihood of those trials succeeding, Anthropic says, and the two plan to expand the work in 2027.
In the post, Michael Pourdehnad, BMS’s head of early clinical development for hematology, oncology and cell therapy, is quoted: “From a single prompt, Claude generated a robust initial analysis that helped inform our assessment of different development options, which would otherwise take days to complete.”
The Acquisition: Mithril Medicine
Anthropic’s drug-development update in four numbers: six partner drug developers, 89% less human review time on Enveda’s manufacturing documents, four hours for a first regulatory draft (about three months by hand), and under 18 months from idea to results in mice at Mithril. Source: Anthropic, 27 October 2026.
Anthropic says Mithril’s founder, Cody Tranbarger, used Claude to organize contracts, logistics and experiments with 11 external labs, and delegated many other parts of the company’s operations to it. Mithril took a possible treatment for one form of muscular dystrophy from an idea to promising results in mice in less than 18 months, according to the post.
Tranbarger is now at Anthropic and plans to start several new programs. If the drug candidates continue to hold up, Anthropic says it expects a drug to be ready to start clinical trials in humans as soon as late 2028. The post does not disclose the price or terms of the acquisition.
Where This Sits in Anthropic’s Business
The post lists the products and programs around the research. They are Claude Science, which it calls its AI workbench for researchers; Claude credits for life scientists; a Life Sciences Verification Program that lets trusted organizations use its most powerful models with more permissive versions of its safeguards; and an open call for guest investigators.
Anthropic says it wants to work with many more biotechnology firms and integrate Claude more deeply into their development processes.
As we read it, the case studies spread Claude across the chain: Anthropic places its six partners at six different stages, from creating a company to planning clinical trials.
As we read it, the clearest numbers are operational, not scientific: Enveda’s document review fell from over 25 hours to under three, and a regulatory draft took four hours instead of about three months, by the companies’ own account.
As we read it, the Mithril deal makes Anthropic a participant: its founder used Claude to run work with 11 external labs, and Anthropic says a candidate could be ready for human trials as soon as late 2028.
Anthropic, 27 October 2026
“There is no single problem to solve; the bottlenecks are distributed all throughout the drug development process”
Three Implications
FOR DRUG DEVELOPERS Anthropic says it wants to work with many more biotechnology firms and integrate Claude more deeply into their development processes.
FOR RESEARCH ORGANIZATIONS Anthropic lists Claude Science, Claude credits for life scientists, a Life Sciences Verification Program and an open call for guest investigators.
FOR INVESTORS IN THE SECTOR Anthropic says The Column Group’s new company Pleiades will use Claude to run many more, and more complex, drug programs than is usual for a small team.
The framework puts it this way: “technical capability has far outpaced organizational readiness.”
As we read it, Anthropic’s post describes the same gap in drug development: it says the best way to find the bottlenecks is to get deeply involved in real drug programs. The framework was written in November 2025 about enterprise AI deployment and does not discuss Anthropic’s life-sciences work.
What Is Not Established
The post gives no financial terms for the six partnerships or the Mithril acquisition, and no revenue figure for Anthropic’s life-sciences work. The time and cost figures are the companies’ own and come from early tests; Anthropic says the work is mostly preclinical.
Anthropic says some programs may lead to new medicines if their trajectories continue. Its own Mithril program and most of the partner work are preclinical; the BMS work concerns an early-stage drug that is already in clinical trials, according to the post.
This Week In The AI Supercycle
Execution Fault Lines, Concentrated Demand, and Geopolitical Firewalls
This week’s issue: the AI build is not short of demand for its parts. It is short of cheap money, and its end revenue rests on a narrow base of large, often venture-funded buyers.
Anthropic says Claude is now working inside six drug developers’ programs, from founding a company to planning clinical trials, and that with Mithril Medicine it is running drug programs of its own, with its own first candidate possibly ready for human trials as soon as late 2028.
A note on sourcing. Details are from Anthropic’s research post “Early progress on accelerating drug development with Claude” and its post on X, both 27 October 2026, read in full. Partner figures are as reported by Anthropic and come from early, mostly preclinical work. This piece covers the business and strategy level only. This is not investment or medical advice.
Gennaro Cuofano is a CRO and tech executive who has worked in AI since late 2015, starting with bringing NLP, natural-language generation, voice and chatbot products to the marketing industry. His background is in law and finance: he holds a Master's degree in Law and an International MBA with an emphasis on corporate finance (LUISS Business School and the University of San Diego, 2012), and worked as a financial analyst at a real-estate investment firm in San Diego and as an assistant controller. His work focuses on business model strategy, business engineering and, more broadly, structural analysis: how companies make money, read from their own filings. He created FourWeekMBA and leads research there and at The Business Engineer, his newsletter on AI and business strategy, with over 95,000 subscribers and more than 1,000 published analyses. His writing has also appeared on Entrepreneur (for example, How to Digitize a Family Business in Europe) and HackerNoon. Find him on LinkedIn and Substack. See how we source.
